TRIANA Biomedicines Announces Publication of Preclinical Data Supporting Clinical Advancement of TRI-611

TRIANA Bio announced publication of preclinical data for TRI-611 supporting potential use in ALK-positive non-small-cell lung cancer (NSCLC), both as a monotherapy and in combination with ALK tyrosine kinase inhibitors. The announcement is an early-stage validation milestone, but it provides no clinical efficacy, safety, financial, or commercialization data.